Clinical Trial Update: Use of Ixmyelocel-T (Formerly Catheter-based Cardiac Repair Cell [CRC]) Treatment in Patients With Heart Failure Due to Dilated Cardiomyopathy [Phase 2]

View source ↗

Summary

Phase 2 trial update on Ixmyelocel-T for heart failure due to dilated cardiomyopathy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dilated Cardiomyopathy
• Heart Failure

Drugs mentioned

• Ixmyelocel-T (Ixmyelocel-T)

Snippet

Sponsor: Vericel Corporation | Conditions: Dilated Cardiomyopathy | Phase 2 | Status: COMPLETED